ETH-CAT

Coronary artery disease, Hypertension, Heart failure, Arrhythmias, Cardiomyopathy

Ethcathinone's primary pharmacological action is potent norepinephrine release (NET EC₅₀ = 99.3 nM). This produces dose-dependent sympathomimetic cardiovascular activation including tachycardia and hypertension. The UK ACMD documents tachycardia, hypertension, arrhythmias, chest pain, and rare myocardial infarction among cathinone class cardiovascular risks. Pre-existing cardiovascular disease or hypertension represents an absolute contraindication.

Epilepsy, History of seizures, Conditions lowering seizure threshold

The sole published clinical case report (Boulanger-Gobeil et al. 2012) documented recurrent tonic-clonic seizures following ingestion of ethcathinone and methylone. While attributed primarily to acute hyponatremia, direct seizure threshold reduction is a class-level cathinone risk. Pre-existing seizure disorders represent an absolute contraindication.

Schizophrenia, Bipolar disorder, Psychotic disorders, Severe anxiety disorders, History of drug-induced psychosis

Weinstein et al. (2017) document that chronic synthetic cathinone use can induce acute psychosis, hypomania, paranoid ideation, and delusions. Ethcathinone's noradrenergic arousal may exacerbate anxiety disorders. Pre-existing psychotic, manic, or severe anxiety disorders represent relative contraindications.

Cirrhosis, Hepatitis, Liver failure, CYP3A4 poor metabolizer status

A pharmacogenetic study (Gomez-Silva et al. 2019) identified CYP3A4 as a primary enzyme in the N-de-ethylation pathway. Hepatic impairment may reduce clearance of ethcathinone, prolonging exposure and increasing toxicity risk. Four metabolizer phenotypes were identified, indicating substantial inter-individual variability.

Pregnancy, Planned pregnancy, Breastfeeding

No reproductive toxicity data for ethcathinone have been published. Sympathomimetic stimulants as a class pose risks to fetal cardiovascular development and placental perfusion. Contraindicated by precautionary principle.

MAO-A inhibitors, MAO-B inhibitors, Non-selective MAOIs

As a monoamine releaser active at NET and SERT, ethcathinone combined with monoamine oxidase inhibitors poses pharmacologically predicted risk of hypertensive crisis or serotonin syndrome. This is a universal class-level contraindication for all monoamine-releasing stimulants.

SSRIs, SNRIs, Tramadol, MDMA, Triptans, St. John's Wort

Ethcathinone releases serotonin from synaptosomes (Nadal-Gratacós et al. 2024). Concurrent use with SSRIs, SNRIs, tramadol, or MDMA creates additive serotonergic risk. The clinical case report documented hyponatremia attributed to serotonergic SIADH when ethcathinone was co-ingested with methylone. Tramadol combination is rated lethal in the interaction database; MDMA combination is rated dangerous.